166 related articles for article (PubMed ID: 36814595)
1. Safety of measles, mumps, and rubella vaccine in adolescents and adults in the vaccine safety Datalink.
Hanson KE; Marin M; Daley MF; Groom HC; Jackson LA; Sy LS; Klein NP; DeSilva MB; Panagiotakopoulos L; Weintraub E; Belongia EA; McLean HQ
Vaccine X; 2023 Apr; 13():100268. PubMed ID: 36814595
[TBL] [Abstract][Full Text] [Related]
2. Vaccines for measles, mumps, rubella, and varicella in children.
Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD004407. PubMed ID: 32309885
[TBL] [Abstract][Full Text] [Related]
3. Vaccines for measles, mumps, rubella, and varicella in children.
Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD004407. PubMed ID: 34806766
[TBL] [Abstract][Full Text] [Related]
4. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
[TBL] [Abstract][Full Text] [Related]
5. Vaccines for measles, mumps and rubella in children.
Demicheli V; Rivetti A; Debalini MG; Di Pietrantonj C
Cochrane Database Syst Rev; 2012 Feb; 2012(2):CD004407. PubMed ID: 22336803
[TBL] [Abstract][Full Text] [Related]
6. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).
McLean HQ; Fiebelkorn AP; Temte JL; Wallace GS;
MMWR Recomm Rep; 2013 Jun; 62(RR-04):1-34. PubMed ID: 23760231
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial.
Lalwani S; Chatterjee S; Balasubramanian S; Bavdekar A; Mehta S; Datta S; Povey M; Henry O
BMJ Open; 2015 Sep; 5(9):e007202. PubMed ID: 26362659
[TBL] [Abstract][Full Text] [Related]
8. Safety of measles-containing vaccines in 1-year-old children.
Klein NP; Lewis E; Fireman B; Hambidge SJ; Naleway A; Nelson JC; Belongia EA; Yih WK; Nordin JD; Hechter RC; Weintraub E; Baxter R
Pediatrics; 2015 Feb; 135(2):e321-9. PubMed ID: 25560438
[TBL] [Abstract][Full Text] [Related]
9. Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: Results from five East European countries.
Prymula R; Povey M; Brzostek J; Cabrnochova H; Chlibek R; Czajka H; Leviniene G; Man S; Neamtu M; Pazdiora P; Plesca D; Ruzkova R; Stefkovicova M; Usonis V; Verdanova D; Wysocki J; Casabona G; Habib MA
Vaccine; 2021 May; 39(19):2643-2651. PubMed ID: 33858718
[TBL] [Abstract][Full Text] [Related]
10. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.
Nolan T; McIntyre P; Roberton D; Descamps D
Vaccine; 2002 Dec; 21(3-4):281-9. PubMed ID: 12450703
[TBL] [Abstract][Full Text] [Related]
11. Second dose of measles-mumps-rubella-varicella vaccine (MMRV) and the risk of febrile convulsions.
Schäfer W; Reinders T; Schink T
Vaccine; 2022 Mar; 40(14):2168-2172. PubMed ID: 35232594
[TBL] [Abstract][Full Text] [Related]
12. Adverse Events Following Measles, Mumps, and Rubella Vaccine in Adults Reported to the Vaccine Adverse Event Reporting System (VAERS), 2003-2013.
Sukumaran L; McNeil MM; Moro PL; Lewis PW; Winiecki SK; Shimabukuro TT
Clin Infect Dis; 2015 May; 60(10):e58-65. PubMed ID: 25637587
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
Vesikari T; Baer M; Willems P
Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
Knuf M; Habermehl P; Zepp F; Mannhardt W; Kuttnig M; Muttonen P; Prieler A; Maurer H; Bisanz H; Tornieporth N; Descamps D; Willems P
Pediatr Infect Dis J; 2006 Jan; 25(1):12-8. PubMed ID: 16395096
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P
Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190
[TBL] [Abstract][Full Text] [Related]
16. Combination Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children: A Systematic Review and Meta-analysis of Immunogenicity and Safety.
Ma SJ; Li X; Xiong YQ; Yao AL; Chen Q
Medicine (Baltimore); 2015 Nov; 94(44):e1721. PubMed ID: 26554769
[TBL] [Abstract][Full Text] [Related]
17. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial.
Prymula R; Bergsaker MR; Esposito S; Gothefors L; Man S; Snegova N; Štefkovičova M; Usonis V; Wysocki J; Douha M; Vassilev V; Nicholson O; Innis BL; Willems P
Lancet; 2014 Apr; 383(9925):1313-1324. PubMed ID: 24485548
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.
Leung JH; Hirai HW; Tsoi KK
Expert Rev Vaccines; 2015; 14(8):1149-57. PubMed ID: 26081133
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia.
Macartney K; Gidding HF; Trinh L; Wang H; Dey A; Hull B; Orr K; McRae J; Richmond P; Gold M; Crawford N; Kynaston JA; McIntyre P; Wood N;
JAMA Pediatr; 2017 Oct; 171(10):992-998. PubMed ID: 28806450
[TBL] [Abstract][Full Text] [Related]
20. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
Knuf M; Zepp F; Helm K; Maurer H; Prieler A; Kieninger-Baum D; Douha M; Willems P
Eur J Pediatr; 2012 Mar; 171(3):463-70. PubMed ID: 21935584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]